TNFRSF8 and neoplasm: Briefly, tumor cells in AITL/FHTCL demonstrated a very characteristic immunophenotypic signature with positive expressions of CD2, CD4, CD5, CD45, and heterogeneous CD7 but negative expressions of surface CD3, CD8, CD16, CD56, CD25, CD26, and CD30.